ASSOCIATION BETWEEN CLONOGENIC CELL-GROWTH AND CLINICAL RISK GROUP IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA
- 1 July 1990
- journal article
- research article
- Vol. 76 (1) , 142-149
Abstract
Chronic lymphocytic leukemia of B-cell origin (B-CLL) is a disease with a variable clinical course, despite the fact that the neoplastic cells in this disorder are homogeneous with respect to morphology, immunophenotype, and cell cycle stage. To further investigate the heterogeneity observed in the clinical behavior of B-CLL, we determined the phenotype and growth requirements of clonogenic cells from 28 patients with B-CLL from low-, intermediate-, and high-risk groups as defined by the Rai staging system. Using methylcellulose as a semi-solid media with feeder cells and/or growth factors, colonies were observed with one or more of the culture conditions tested in 25 of 28 CLLs. Phenotypic analysis of colonies demonstrated that the clonogenic cells uniformly expressed Ia, CD19, CD20, CD5, and the identical light chain as the original CLL cell cultured. However, heterogeneity was observed in clonogenic B-CLL cell growth among the three different CLL risk groups. Clonogenic cells from patients with low-risk CLL required either irradiated unstimulated T cells, with or without conditioned media (CM) or irradiated activated T cells alone for colony formation. Both the number of colonies (227 .+-. 15) as well as the number of cells per colony (220 .+-. 82) were large, with a mean cloning efficiency of 0.39%. In contrast, clonogenic cells from patients with intermediate- and high-risk CLL required the combination of both irradiated activated T cells and CM. As compared with low-risk CLLs, both the number and size of the colonies formed by the intermediate- (74 .+-. 17, 70 .+-. 39) and high- (83 .+-. 28, 40 .+-. 14) risk groups were significantly lower (P < .001). Similarly, the mean cloning efficiency was significantly reduced to 0.15% and 0.14%, respectively. None of the recombinant cytokines (interleukin 1 [IL-1] to IL-7, tumor necrosis factor, .alpha. and .gamma.-interferon, B-cell growth factor, and granulocyte macrophage colony- stimulating factor) alone or in combination with each other could entirely replace the stimulatory effect of the activated T cells. These data suggest that clinical progression of B-CLL is associated with a loss of clonogenic potential in the circulating pool of neoplastic cells, which require as yet undefined factors provided by activated T cells and CM.This publication has 20 references indexed in Scilit:
- CHRONIC LYMPHOCYTIC-LEUKEMIA PROGENITOR CELLS CARRY THE ANTIGENS T65, BA-1, AND IA1983
- Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia.The Journal of Experimental Medicine, 1982
- MONOCLONAL CLL B-CELLS MAY BE INDUCED TO GROW IN AN INVITRO B-CELL COLONY ASSAY SYSTEM1982
- A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas.The Journal of Immunology, 1981
- Colony formation by normal and malignant human B-lymphocytesBritish Journal of Cancer, 1980
- Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin.The Journal of Immunology, 1980
- A methodological study of E-rosette formation using AET-treated sheep red blood cellsJournal of Immunological Methods, 1979
- A method for cloning T‐lymphocytic precursors in agarAmerican Journal of Hematology, 1979
- Mouse Red-Cell Rosettes in B-Lymphoproliferative DisordersBritish Journal of Haematology, 1976
- ROSETTE-FORMATION WITH MOUSE ERYTHROCYTES .2. MARKER FOR HUMAN B AND NON-T LYMPHOCYTES1976